New weapon against superbug e. coli tested in cancer transplant patients
Disease control
Recruiting now
This study tests an experimental oral drug called SNIPR001 in 24 adults with blood cancer who are scheduled for a stem cell transplant and carry a fluoroquinolone-resistant E. coli infection. Participants receive SNIPR001 or a placebo alongside standard antibiotic care. The goal …
Phase: PHASE1, PHASE2 • Sponsor: SNIPR Biome Aps. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC